Asia
Suven Life Sciences Logs 76% Patient Enrollment Rate for Phase 3 Alzheimer's Drug Study
Suven Life Sciences' (NSE:SUVEN, BOM:530239) global phase 3 study for Masupirdine in agitation associated with Alzheimer's dementia achieved 76% patient enrollment.The 375-patient study is being conducted across Europe and North America, according to a Tuesday filing on Indian bourses.Patient enrollment is expected to be complete by September 2026, with data readout targeted for April 2027.
BOM:530239NSE:SUVEN
